<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01663935</url>
  </required_header>
  <id_info>
    <org_study_id>2016-1576</org_study_id>
    <secondary_id>2012-0023</secondary_id>
    <nct_id>NCT01663935</nct_id>
  </id_info>
  <brief_title>Vision Response to Dopamine Replacement</brief_title>
  <official_title>Interventional Study of Levodopa Replacement on Retinal Function in Oculocutaneous Albinism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate and document physiologic and functional changes in
      visual performance and retinal function of patients diagnosed with albinism (a dopamine
      deficiency state) following a trial of oral Levodopa/carbidopa treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study the investigators propose that the retina itself in albinism is deficient in
      dopamine, and vision improvement will occur as a result of improved retinal function in
      response to the deficient neurotransmitter dopamine. This study has a pretest-posttest design
      in order to determine if improvement in vision is in response to replacement of deficiency
      (dopamine). The ERG testing and OCT will be critical determinants to confirm vision
      improvement as a result of improved retinal function, but are not primary outcome data. Main
      outcome measures will be collected at pre-treatment, 1 month, 3 months, and 4 months. Change
      in visual acuity as measured in logMAR by Snellen or SVEP after 3 months of treatment is the
      primary outcome. Patients include OCA1a patients, OCA1b, OCA2, and unclassified OCA. OCA1a
      patients clinically are known to have the worst vision, and physiologically have the lowest
      (or absent) levels of tyrosinase function (Dopamine Production). All patients will be treated
      with Levodopa/carbidopa 4mg/kg/day in three divided doses.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity Improvement</measure>
    <time_frame>3 months</time_frame>
    <description>Change in visual acuity as measured in logMAR by Snellen or Sweep visual evoked potential (SVEP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal Function</measure>
    <time_frame>3 months</time_frame>
    <description>Electroretinography -- electro physiologic testing of retinal function</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Color and Contrast sensitivity</measure>
    <time_frame>3 months</time_frame>
    <description>Ancillary testing of visual/retinal function</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Albinism</condition>
  <condition>Oculocutaneous Albinism</condition>
  <arm_group>
    <arm_group_label>Levodopa/carbidopa 4mg/kg/day</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment drug taken orally three times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa/carbidopa</intervention_name>
    <description>This study will have an intent to treat goal. Anyone that fits the inclusion criteria for the study will be entered and receive study drug.</description>
    <arm_group_label>Levodopa/carbidopa 4mg/kg/day</arm_group_label>
    <other_name>Sinemet</other_name>
    <other_name>Atamet</other_name>
    <other_name>Parcopa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of oculocutaneous albinism

          -  age over 3 and weight over 25 lbs.

        Exclusion Criteria:

          -  ocular only albinism

          -  ocular pathology other than albinism

          -  neurologic disease, history of myocardial infarction, history of clinical depression,
             pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael C Struck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael C Struck, MD</last_name>
    <phone>608-263-9859</phone>
    <email>mcstruck@wisc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angie Wealti</last_name>
    <phone>608-265-7557</phone>
    <email>Angie Wealti &lt;wealti@ophth.wisc.edu&gt;</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angie Wealti</last_name>
      <phone>608-265-7557</phone>
      <email>Angie Wealti &lt;wealti@ophth.wisc.edu&gt;</email>
    </contact>
    <investigator>
      <last_name>Michael C Struck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2012</study_first_submitted>
  <study_first_submitted_qc>August 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2012</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>levodopa</keyword>
  <keyword>Albinism</keyword>
  <keyword>dopamine</keyword>
  <keyword>oculocutaneous albinism</keyword>
  <keyword>vision</keyword>
  <keyword>retina function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albinism</mesh_term>
    <mesh_term>Albinism, Oculocutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Dopamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

